Avalo Therapeutics Announces Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)
Avalo Therapeutics Inc AVTX
$15.58
▲ +3.32%
(+$0.50)
⬆️ Above Yest. High
🔥 High Short Interest
Open
$15.16
Prev Close
$15.08
Day Range
$14.74 – $15.67
52W Range
$10.70 – $24.27
Market Cap
$835.56M
Beta
0.63
EPS (TTM)
$-4.75
📋 Company Profile
| Industry | Biotechnology |
| Country | US |
| Exchange | NASDAQ NMS - GLOBAL MARKET |
| Currency | USD |
| IPO Date | 2015-11-13 |
| Shares Out. | 52,900,000 |
| Website | avalotx.com/ ↗ |
| Phone | 14105228707 |
| Employees | 33 |
| Revenue | $0 |
| Gross Profit | $0 |
| Net Income | -$36.4M |
| Free Cash Flow | -$68.3M |
| Total Assets | $490.8M |
| Total Liabilities | $42.1M |
| Equity | $448.7M |
About Avalo Therapeutics Inc
Avalo Therapeutics Inc is a clinical stage biotechnology company fully dedicated to developing IL-1B-based treatments for immune-mediated inflammatory diseases. The company's asset is Abdakibart (AVTX-009) an anti-IL-1B monoclonal antibody ("mAb"), targeting inflammatory diseases. Avalos pipeline also includes quisovalimab (anti-LIGHT mAb) and AVTX-008 (BTLA agonist fusion protein), AVTX-006 and AVTX-913.
Avalo Therapeutics Inc is a publicly traded company under the ticker symbol AVTX on the NASDAQ NMS - GLOBAL MARKET, operating in the Biotechnology industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.
📊 Analyst Ratings
21 analysts (2026-09-01)